- DRL is keenly tweaking its portfolio through core and non-core products
- The company is particular on cardiovascular and oncology therapy areas would be key to achieve necessary growth in India
IndiGlobal Bureau
Aiming for a long-term growth strategy and leadership in the Indian market, Dr. Reddy’s sees to opt for a differentiated portfolio states Global Data’s Pharma Intelligence Center. GlobalData, a data and analytics company said that the differenciated approach of Dr. Reddy’s Laboratories (DRL) to its product offerings is a key part of growth strategy in India. (DRL) has been strategizing to become a top company in the Indian pharmaceutical market.
The company has been entering into deals and also divesting at the same time. DRL has been involved in five deals related to marketed products in India, consisting of three product divestment deals and two brand rights acquisitions.
The company’s focus is on building strong brands and excelling in selected therapy areas. In line with this goal, the company has been divesting non-core brands that do not align with its growth objectives and acquiring product rights from other companies to strengthen its portfolio, it stated. It may be noted that DRL divested nine dermatology brands, four paediatric brands and in May 22, the company divested four brands, including one brand in gynaecology segment and three brands in urology segment, to Torrent Pharmaceuticals.
“DRL’s aim is to be among the top five pharma companies in India. To achieve this, DRL is focusing on various tactics, including building big brands, winning in chosen therapy areas through a differentiated portfolio and inorganic growth,” Prashant Khadayate, Pharma Analyst at GlobalData, said in a statement.
In April 2022, the company acquired the cardiovascular brand Cidmus (valsartan and sacubitril) from Novartis, which is used to treat heart failure patients. Then, in January 2023, it obtained trademark rights for the breast cancer drug Primcyv (palbociclib) from Pfizer.
DRL is keenly tweaking its portfolio through core and non-core products. The company is particular on cardiovascular and oncology therapy areas would be key to achieve necessary growth in India. Oncology market has huge potential.